Why was this study done? People with Meibomian Gland Dysfunction (MGD) often have dry, irritated eyes because the tiny oil glands in their eyelids do not work properly. Applying gentle heat to the eyelids is a common way to improve the flow of oil and relieve symptoms. This study wanted to find out whether a USB-powered warm compress or a self-heating disposable eye mask works better and feels more comfortable for patients with MGD. Who took part? Adults diagnosed with Meibomian Gland Dysfunction were invited to participate. Each person tried both treatments, one after the other, with a short break between them (this is called a crossover design). What did participants do? In one treatment phase, participants used a USB-powered warm compress for about 10 minutes per day over two weeks. In the other phase, they used a self-heating disposable eye mask for the same amount of time. The order of treatments was randomized to avoid bias. Before and after each treatment, eye tests and comfort questionnaires were completed. What did the study measure? The main goal was to see if the treatments improved: Tear film stability (how long the tears stay on the eye surface) Meibomian gland function (how well the glands release oil) Eye comfort and dryness symptoms What were the results? Both the USB-powered warm compress and the self-heating eye mask helped improve tear stability and comfort. However, the USB-powered device provided slightly better results in improving gland function and patient satisfaction. No serious side effects or discomfort were reported. What do these results mean? Regular eyelid warming is an effective way to manage MGD and dry eye symptoms. Both devices are safe and easy to use, but a USB-powered warm compress may offer stronger and more consistent heat for better results. Patients and eye-care professionals can choose the device that best fits daily routines, comfort, and lifestyle. Who conducted the study? The study was carried out by optometrists and vision scientists specializing in ocular surface disease and dry eye therapy. It followed ethical approval and was reviewed by an institutional research board before beginning. Why is this study important? MGD is one of the most common causes of dry eye disease worldwide. Understanding which home-based treatment works best helps patients, families, and clinicians make informed choices about safe and effective care options.
Age range
18 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Tear Meniscus Height
Timeframe: Baseline at Day 1, post intervention at Day 3 and post intervention at Day 5.
Ocular Surface Disease Index
Timeframe: Baseline
tear break-up time
Timeframe: Baseline at Day 1, post intervention at Day 3 and post intervention at Day 5.
Standard Patient Evaluation of Eye Dryness
Timeframe: Baseline at Day 1 and post intervention at Day 5.